12 results on '"Martinage G"'
Search Results
2. [Conformal radiotherapy for vertebral bone metastasis]
- Author
-
Faivre, Jc, Py, Jf, Vogin, G., Martinage, G., Salleron, J., Royer, P., Grandgirard, N., Pasquier, D., Thureau, S., Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), and Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)
- Subjects
Organs at Risk ,Spinal Neoplasms ,Radiotherapy ,Soins oncologiques de supports ,Conformal ,Intensity-modulated ,Vertèbre ,Pain ,Bone metastasis ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Métastase osseuse ,Decompression, Surgical ,Spine ,Douleur ,Patient Education as Topic ,Back Pain ,Quality of Life ,Humans ,Radiotherapy, Conformal ,Spinal Cord Compression ,Supportive care ,Radiotherapy, Image-Guided ,Radiothérapie - Abstract
International audience; Analgesic external beam radiation therapy is a standard of care for patients with uncomplicated painful bone metastases and/or prevention of bone complications. In case of fracture risk, radiation therapy is performed after surgery in a consolidation of an analgesic purpose and stabilizing osteosynthesis. Radiotherapy is mandatory after vertebroplasty or kyphoplasty. Spinal cord compression - the only emergency in radiation therapy - is indicated postoperatively either exclusively for non surgical indication. Analgesic re-irradiation is possible in the case of insufficient response or recurrent pain after radiotherapy. Metabolic radiation, bisphosphonates or denosumab do not dissuade external radiation therapy for pain relief. Systemic oncological treatments can be suspended with a period of wash out given the risk of radiosensitization or recall phenomenon. Better yet, the intensity modulated radiotherapy and stereotactic radiotherapy can be part of a curative strategy for oligometastatic patients and suggest new treatment prospects.
- Published
- 2016
3. EP-1521 IMRT for prostate cancer with seminal vesicle involvement : A multicentric retrospective analysis
- Author
-
Goupy, F., Supiot, S., Pasquier, D., Latorzeff, I., Schick, U., Monpetit, E., Martinage, G., Hervé, C., Le Proust, B., Castelli, J., and De Crevoisier, R.
- Published
- 2019
- Full Text
- View/download PDF
4. EP-1257 Post-operative hypo-fractionated SBRT in a large series of patients with brain metastases
- Author
-
Martinage, G., Geffrelot, J., Stefan, D., Bogart, E., Rault, E., Reyns, N., Emery, E., Martinage Makhloufi, S., Mouttet Audouard, R., Basson, L., Mirabel, X., Lartigau, E., and Pasquier, D.
- Published
- 2019
- Full Text
- View/download PDF
5. PO-0841 Salvage SBRT for local prostate cancer recurrence after radiotherapy: a GETUG retrospective study
- Author
-
Martinage, G., Janoray, G., Rojas, D.P., Zerini, D., Goupy, F., De Crevoisier, R., Bogart, E., Calais, G., Toledano, A., Chauveinc, L., Scher, N., Bondiau, P.Y., Hannoun-Levi, J.M., Silva, M., Meyer, E., Nickers, P., Lacornerie, T., Lartigau, E., Jereczek-Fossa, B.A., and Pasquier, D.
- Published
- 2019
- Full Text
- View/download PDF
6. Place et modalités de l'irradiation postopératoire dans la prise en charge des métastases cérébrales.
- Author
-
Pasquier, D., Mouttet Audouard, R., Martinage, G., Lacornerie, T., Mirabel, X., and Lartigau, E.
- Abstract
Les métastases sont les tumeurs cérébrales les plus fréquentes. Après chirurgie, la radiothérapie en conditions stéréotaxiques du lit opératoire est devenue le standard. Les données de deux essais randomisés montrent que la radiothérapie en conditions stéréotaxiques permet un bon taux de contrôle local par rapport à la surveillance, tout en diminuant le risque de troubles cognitifs et d'altération de la qualité de vie en comparaison avec l'irradiation de l'encéphale en totalité. Le taux de contrôle local paraît plus élevé après radiothérapie en conditions stéréotaxiques hypofractionnée par rapport à la radiothérapie en conditions stéréotaxiques en séance unique. Des questions restent ouvertes, comme la définition des volumes cibles, le schéma optimal en particulier pour les cavités opératoires de grande taille, les stratégies pour diminuer le risque de récidive leptoméningée et la séquence thérapeutique. Metastases are the most common brain tumors. After surgery, stereotactic radiotherapy (SRT) of the resection cavity is the standard of care. Data from two randomized trials indicate that SRT to the surgical bed is an effective treatment in reducing local failure as compared with observation, while reducing the risk of cognitive deterioration and maintaining quality of life as compared with whole brain radiation therapy. Local control appears higher after hypofractionated SRT compared to single-fraction SRT. Several questions such as target volumes, the optimal regimen in particular for large tumor bed, strategies to reduce the risk of lepto-meningeal recurrence, and the treatment sequence still need to be answered. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
- Author
-
Pasquier D, Peiffert D, Nickers P, Maingon P, Pommier P, Lacornerie T, Martinage G, Tresch E, and Lartigau E
- Subjects
- Aged, Aged, 80 and over, Erectile Dysfunction epidemiology, Fiducial Markers, Humans, Male, Middle Aged, Organs at Risk radiation effects, Outcome Assessment, Health Care, Prevalence, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Radiation Dose Hypofractionation, Radiosurgery adverse effects, Radiosurgery instrumentation, Radiosurgery mortality, Re-Irradiation adverse effects, Rectum radiation effects, Time Factors, Treatment Outcome, Urinary Bladder radiation effects, Urination Disorders epidemiology, Prostatic Neoplasms radiotherapy, Radiosurgery methods, Re-Irradiation methods
- Abstract
Purpose: The aim of this analysis was to assess the 5-year tolerance and survival in patients undergoing hypofractionated stereotactic boost after external beam radiation therapy (EBRT) for intermediate-risk prostate cancer., Methods and Materials: Between August 2010 and April 2013, 76 patients with intermediate-risk prostate carcinoma were included in the study. A first course delivered 46 Gy using conventional fractionation. The second course delivered a boost of 18 Gy (3 × 6 Gy) within 10 days using stereotactic body radiation therapy (SBRT). Gastrointestinal and genitourinary toxicities were assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v4.0. Secondary outcome measures were overall, biochemical relapse-free, and relapse-free survival; prostate-specific antigen kinetics; and patient functional status (urinary and sexual) according to the International Index of Erectile Function and International Prostate Symptom Score questionnaires., Results: Sixty patients (79%) were treated by CyberKnife and 16 (21%) by linear accelerator. Median follow-up was 62 months (range, 29-69). The cumulative incidence of genitourinary and gastrointestinal grade ≥2 toxicities at month 60 after the end of radiation therapy was 1.4% (95% confidence interval [CI], 0.1%-6.6%) and 9.3% (95% CI, 4.1%-17.1%), respectively. Biochemical relapse-free and relapse-free survival rates at 5 years were 87.4% (95% CI, 77.1%-93.2%) and 86.2% (95% CI, 75.8-92.3), respectively. The mean (standard deviation) prostate-specific antigen variation within 3 months and 5 years post-radiation therapy was -1.20 ng/mL/mo (0.79) and -1.30 ng/mL/y (1.05), respectively. There was no significant difference between the International Prostate Symptom quality of life score between inclusion and month 60. For the International Index of Erectile Function, there was a significant difference between inclusion and month 60 (P = .005), with a higher proportion of severe/noninterpretable disorders at 60 months., Conclusions: The results of the trial demonstrate that the EBRT and SBRT combination is well tolerated and yields good efficacy results. These data provide a good basis for comparing EBRT and brachytherapy boost to EBRT and SBRT boost in future prospective studies., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
8. Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG.
- Author
-
Pasquier D, Martinage G, Janoray G, Rojas DP, Zerini D, Goupy F, De Crevoisier R, Bogart E, Calais G, Toledano A, Chauveinc L, Scher N, Bondiau PY, Hannoun-Levi JM, Silva M, Meyer E, Nickers P, Lacornerie T, Jereczek-Fossa BA, and Lartigau E
- Subjects
- Aged, Aged, 80 and over, Androgen Antagonists therapeutic use, Disease-Free Survival, Gastrointestinal Diseases etiology, Humans, Kallikreins blood, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Male, Male Urogenital Diseases etiology, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local diagnostic imaging, Neoplasm Recurrence, Local pathology, Positron-Emission Tomography, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology, Retrospective Studies, Survival Rate, Tumor Burden, Neoplasm Recurrence, Local radiotherapy, Prostatic Neoplasms radiotherapy, Radiosurgery, Salvage Therapy methods
- Abstract
Purpose: To assess the efficacy and safety of salvage stereotactic body radiation therapy (SBRT) in patients with biopsy-proven local prostate cancer recurrence after radiation therapy., Methods and Materials: Between April 2010 and January 2017, 100 patients were included in 7 centers. Disease extension was assessed by pelvic multiparametric magnetic resonance imaging and choline positron emission tomography in 87% and 94% of patients, respectively. The median time interval between the 2 treatments was 7.5 years (range, 2-18). Median prostate-specific antigen at recurrence was 4.3 ng/mL (range, 2-38). Median SBRT dose was 36 Gy (range, 25-36.25) in 6 fractions (range, 5-6), every other day. Thirty-four percent of patients were treated by androgen deprivation therapy for a median duration of 12 months. Toxicity was assessed according to Common Terminology Criteria for Adverse Events version 4.03., Results: Median follow-up was 29.3 months (range, 4-91). Second biochemical recurrence-free survival rate at 3 years was 55% (95% confidence interval [CI], 42%-66%). The initial D'Amico group, time interval after first radiation therapy, and SBRT dose were prognostic factors of biochemical recurrence-free survival in multivariate analysis (P = .09, P = .025, P = .018, respectively). No patient developed acute gastrointestinal toxicity of grade >1; rates of acute genitourinary toxicity of grade 2 and 3 were 8% and 1%, respectively. The actuarial 3-year grade ≥2 genitourinary and gastrointestinal toxicity was 20.8% (95% CI, 13%-29%) and 1% (95% CI, 0.1%-5.1%), respectively. One patient presented with neuritis of grade 3., Conclusions: With a short follow-up, this study shows that salvage SBRT allows for encouraging control and acceptable toxicity. Further prospective studies are necessary to confirm these preliminary results and to determine late toxicity., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
9. Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases.
- Author
-
Martinage G, Geffrelot J, Stefan D, Bogart E, Rault E, Reyns N, Emery E, Makhloufi-Martinage S, Mouttet-Audouard R, Basson L, Mirabel X, Lartigau E, and Pasquier D
- Abstract
Purpose: The aim of this study was to assess, in a large series, the efficacy and tolerance of post-operative adjuvant hypofractionated stereotactic radiation therapy (HFSRT) for brain metastases (BMs). Materials and Methods: Between July 2012 and January 2017, 160 patients from 2 centers were operated for BM and treated by HFSRT. Patients had between 1 and 3 BMs, no brainstem lesions or carcinomatous meningitis. The primary endpoint was local control. Secondary endpoints were distant brain control, overall survival (OS) and tolerance to HFSRT. Results: 73 patients (46%) presented with non-small cell lung cancer (NSCLC), 23 (14%) had melanoma and 21 (13%) breast cancer. Median age was 58 years (range, 22-83 years). BMs were synchronous in 50% of the cases. The most frequent prescription regimens were 24 Gy in 3 fractions ( n = 52, 33%) and 30 Gy in 5 fractions ( n = 37, 23%). Local control rates at 1 and 2 years were 88% [95%CI, 81-93%] and 81% [95%CI, 70-88%], respectively. Distant control rate at 1 year was 48% [95%CI, 81-93%]. In multivariate analysis, primary NSCLC was associated with a significant reduction in the risk of death compared to other primary sites (HR = 0.57, p = 0.007), the number of extra-cerebral metastatic sites (HR = 1.26, p = 0.003) and planning target volumes (HR = 1.15, p = 0.012) were associated with a lower OS. There was no prognostic factor of time to local progression. Median OS was 15.2 months [95%CI, 12.0-17.9 months] and the OS rate at 1 year was 58% [95% CI, 50-65%]. Salvage radiotherapy was administered to 72 patients (45%), of which 49 received new HFSRT. Ten (7%) patients presented late grade 2 and 4 (3%) patients late grade 3 toxicities. Thirteen (8.9%) patients developed radiation necrosis. Conclusions: This large multicenter retrospective study shows that HFSRT allows for good local control of metastasectomy tumor beds and that this technique is well-tolerated by patients.
- Published
- 2019
- Full Text
- View/download PDF
10. Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis.
- Author
-
Goupy F, Supiot S, Pasquier D, Latorzeff I, Schick U, Monpetit E, Martinage G, Hervé C, Le Proust B, Castelli J, and de Crevoisier R
- Subjects
- Adult, Aged, Aged, 80 and over, Androgen Antagonists adverse effects, Chemoradiotherapy, Digestive System Diseases chemically induced, Digestive System Diseases diagnosis, Humans, Lymph Nodes drug effects, Lymph Nodes radiation effects, Magnetic Resonance Imaging methods, Male, Middle Aged, Prostate diagnostic imaging, Prostate drug effects, Prostate radiation effects, Radiation Injuries diagnosis, Radiation Injuries etiology, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated adverse effects, Retrospective Studies, Seminal Vesicles diagnostic imaging, Seminal Vesicles drug effects, Seminal Vesicles radiation effects, Androgen Antagonists therapeutic use, Prostatic Neoplasms drug therapy, Prostatic Neoplasms radiotherapy, Radiotherapy, Intensity-Modulated methods
- Abstract
Objectives: No study has reported clinical results of external-beam radiotherapy specifically for T3b prostate cancer. The possibility of escalating the dose to the involved seminal vesicles (ISV) while respecting the dose constraints in the organs at risk is thus so far not clearly demonstrated. The objective of the study was to analyze the dose distribution and the clinical outcome in a large series of patients who received IMRT for T3b prostate cancer., Materials and Methods: This retrospective analysis included all patients who received IMRT and androgen deprivation therapy for T3b prostate cancer, between 2008 and 2017, in six French institutions, with available MRI images and dosimetric data., Results: A total of 276 T3b patients were included. The median follow-up was 26 months. The median (range) prescribed doses (Gy) to the prostate and to the ISV were 77 (70-80) and 76 (46-80), respectively. The dose constraint recommendations were exceeded in less than 12% of patients for the rectum and the bladder. The 5-year risks of biochemical and clinical recurrences and cancer-specific death were 24.8%, 21.7%, and 10.3%, respectively. The 5-year risks of local, pelvic lymph node, and metastatic recurrences were 6.4%, 11.3%, and 15%, respectively. The number of involved lymph nodes (≤ 2 or ≥ 3) on MRI was the only significant prognostic factor in clinical recurrence (HR 9.86) and death (HR 2.78). Grade ≥ 2 acute and 5-year late toxicity rates were 13.2% and 12% for digestive toxicity, and 34% and 31.5% for urinary toxicity, respectively. The dose to the pelvic lymph node and the age were predictive of late digestive toxicity., Conclusion: IMRT for T3b prostate cancer allows delivery of a curative dose in the ISV, with a moderate digestive toxicity but a higher urinary toxicity. Lymph node involvement increases the risk of recurrence and death., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
11. Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance.
- Author
-
Martinage G, Hong AM, Fay M, Thachil T, Roos D, Williams N, Lo S, and Fogarty G
- Subjects
- Adult, Aged, Aged, 80 and over, Australia, Brain Neoplasms secondary, Cranial Irradiation standards, Dose Fractionation, Radiation, Female, Humans, Male, Melanoma secondary, Middle Aged, Organ Sparing Treatments standards, Organ Sparing Treatments statistics & numerical data, Radiosurgery methods, Radiosurgery standards, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Intensity-Modulated standards, Retrospective Studies, Young Adult, Brain Neoplasms radiotherapy, Cranial Irradiation methods, Hippocampus radiation effects, Melanoma radiotherapy, Organ Sparing Treatments methods, Quality Assurance, Health Care, Radiation Injuries prevention & control, Radiotherapy, Intensity-Modulated methods
- Abstract
Background: Melanoma brain metastases (MBM) often cause morbidity and mortality for stage IV melanoma patients. An ongoing randomised phase III trial (NCT01503827 - WBRT-Mel) evaluates the role of adjuvant whole brain radiotherapy (WBRT) following local treatment of MBM. Hippocampal avoidance during WBRT (HA-WBRT) has shown memory and neurocognitive function (NCF) preservation in the RTOG-0933 phase II study. This study assessed the quality assurance of HA-WBRT within the WBRT-Mel trial according to RTOG-0933 study criteria., Methods: Hippocampal avoidance was allowed in approved centres with intensity-modulated radiotherapy capability. Patients treated by HA-WBRT were not randomized within the WBRT arm. The RTOG 0933 contouring Atlas was used to contour hippocampi. In the trial co-ordinating centre, patients were treated with volumetric modulated arc therapy using complementary arcs; similar techniques were used at other sites. Dosimetric data were extracted retrospectively and analysed in accordance with RTOG 0933 study constraints criteria., Results: Among the 215 patients accrued to the WBRT-Mel study between April 2009 and September 2017, 107 were randomized to the WBRT arm, 22 were treated by HA-WBRT in 4 centers. Eighteen patients were treated in the same centre. The median age was 65 years. The commonest (91%) HA-WBRT schema was 30 Gy in 10 fractions. Prior to HA-WBRT, 10 patients had been treated by surgery alone, six by radiosurgery alone, four by surgery and radiosurgery and two exclusively by simultaneous integrated boost concurrent to HA-WBRT. Twenty patients were treated with intention to spare both hippocampi and two patients had MBM close to one hippocampus and were treated with intention to spare the contralateral hippocampus. According to RTOG-0933 study criteria, 18 patients (82%) were treated within constraints and four patients (18%) had unacceptable deviation in just one hippocampus., Conclusions: This dosimetric quality assurance study shows good compliance (82%) according to RTOG-0933 study dosimetric constraints. Indeed, all patients respected RTOG hippocampal avoidance constraints on at least one hippocampus. In the futureanalysis of the WBRT-Mel trial, the NCF of patients on the observation arm, WBRT arm and with HA-WBRT arm will be compared.
- Published
- 2018
- Full Text
- View/download PDF
12. Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
- Author
-
Pasquier D, Nickers P, Peiffert D, Maingon P, Pommier P, Lacornerie T, Martinage G, Tresch E, and Lartigau E
- Subjects
- Aged, Aged, 80 and over, Humans, Male, Middle Aged, Radiotherapy, Intensity-Modulated, Prostatic Neoplasms radiotherapy
- Abstract
Purpose: Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer., Methods and Material: Between August 2010 and April 2013, 76 patients with intermediated-risk prostate carcinoma were included in the study. A first course delivered 46 Gy by IMRT (68.4% of patients) or 3D conformal radiotherapy (31.6% of patients). The second course delivered a boost of 18 Gy (3x6Gy) within 10 days. Gastrointestinal (GI) and genitourinary (GU) toxicities were evaluated as defined by NCI-CTCAE (v4.0). Secondary outcome measures were local control, overall and metastasis-free survival, PSA kinetics, and patient functional status (urinary and sexual) according to the IIEF5 and IPSS questionnaires., Results: The overall treatment time was 45 days (median, range 40-55). Median follow-up was 26.4 months (range, 13.6-29.9 months). Seventy-seven per cent (n = 58) of patients presented a Gleason score of 7. At 24 months, biological-free survival was 98.7% (95% CI, 92.8-99.9%) and median PSA 0.46 ng/mL (range, 0.06-6.20 ng/mL). Grade ≥2 acute GI and GU toxicities were 13.2% and 23.7%, respectively. Grade ≥2 late GI and GU toxicities were observed in 6.6% and 2.6% of patients, respectively. No grade 4 toxicity was observed., Conclusions: Hypofractionated stereotactic boost is effective and safely delivered for intermediate-risk prostate carcinoma after conventional radiation. Mild-term relapse-free survival and tolerance results are promising, and further follow-up is warranted to confirm the results at long term., Trial Registration: ClinicalTrials.gov NCT01596816.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.